NASDAQ:AKTX Akari Therapeutics Q4 2025 Earnings Report $9.16 -0.72 (-7.29%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$9.38 +0.22 (+2.40%) As of 09/18/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Akari Therapeutics EPS ResultsActual EPS-$2.68Consensus EPS -$0.03Beat/MissMissed by -$2.65One Year Ago EPSN/AAkari Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkari Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETUpcoming EarningsAkari Therapeutics' Q3 2026 earnings is estimated for Friday, December 4, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Akari Therapeutics Earnings HeadlinesAkari Therapeutics (NASDAQ:AKTX) Stock Passes Above 50 Day Moving Average - What's Next?September 17 at 3:01 AM | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Share Price Crosses Above Fifty Day Moving Average - Here's What HappenedSeptember 9, 2026 | americanbankingnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 20 at 1:00 AM | American Alternative (Ad)Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsSeptember 8, 2026 | globenewswire.comAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceAugust 27, 2026 | globenewswire.comAkari targets mid-2027 for human trial of differentiated cancer therapyAugust 18, 2026 | msn.comSee More Akari Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email. Email Address About Akari TherapeuticsAkari Therapeutics (NASDAQ:AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression. Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation. The company is also developing PAS-nomacopan, a longer-acting formulation intended to extend treatment duration. The company has investigated its therapies in conditions including pediatric hematopoietic stem-cell-transplant-associated thrombotic microangiopathy and bullous pemphigoid. Akari’s programs remain in clinical development, and its therapies have not been established as approved treatments for these indications. Akari Therapeutics is headquartered in the United Kingdom and conducts its development activities through international clinical and research programs. The company is led by Chief Executive Officer Clive Richardson and is listed on the Nasdaq Capital Market under the symbol AKTX.View Akari Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
